A Phase 2/3 interventional study of adalimumab and adalimumab in Psoriasis, sponsored by Abbott. Completed at 64 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-04-08.
Sponsored by Abbott · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.
Among the 48 studies testing adalimumab in Psoriasis, this one is the 26th largest by enrollment, is the only one that started in 2006, is the only one in phase 2/3, and was the 10th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
South Valley University · Sites in Egypt
Ages 18–70 · Healthy volunteers
Mabscale, LLC · Sites in Russian Federation
Ages 18–65
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ages 4–17
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 27 · Phase 4 11
First in 2003; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 147 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 148 across the 48 interventional studies. Of the 41 that completed or were terminated, 27 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 48 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
16 studies in Psoriasis by Abbott: none open now, none under way, none of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 16 studies in Psoriasis by Abbott, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2006, is one of 2 in phase 2/3, and was the 12th registered.
Abbott’s Psoriasis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 48 studies testing adalimumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 16 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with psoriasis
This was a continuation trial of adalimumab in participants with moderate to severe chronic plaque psoriasis who had completed Study M04-688 (NCT00338754), a 24-week, double-blind, placebo-controlled study. This study was an open-label extension study that continued until the approval of adalimumab for the treatment of psoriasis in Japan.
During Study M04-688 (NCT00338754), participants received 24 weeks of treatment with adalimumab 40 mg every other week (eow) with or without a loading dose, adalimumab 80 mg eow, or placebo.
At the start of this study, participants who had received adalimumab 40 mg eow or adalimumab 80 mg eow in Study M04-688 (NCT00338754) continued on the same treatment regimen. Participants who had received placebo during Study M04-688 (NCT00338754) were re-randomized at the start of this study to receive adalimumab 40 mg eow or adalimumab 80 mg eow.
Participants in the adalimumab 40 mg eow treatment group who failed to achieve a PASI50 response (>= 50% reduction in the Psoriasis Area and Severity Index score from Baseline of Study M04-688 [NCT00338754]) at or anytime after Week 12 of this study were given the option to increase their dose to adalimumab 80 mg eow. Once the dose was escalated, there was no option to de-escalate dosing back to 40 mg eow. Participants who failed to achieve PASI50 responses while receiving adalimumab 80 mg eow may have been discontinued from the study after evaluating the risk/benefit of further treatment with adalimumab.
At Week 28 of this study, it was mandatory for all participants who started the study in the adalimumab 80 mg eow treatment group (i.e., not including the dose escalators described above) to reduce their dose to adalimumab 40 mg eow, regardless of their response status. Following this mandatory dose reduction, if these participants failed to achieve or maintain PASI50 response, they were permitted to escalate their dose to adalimumab 80 mg eow. There was no option to de-escalate dosing back to 40 mg eow following dose escalation.
Data in this clinical trial results disclosure are analyzed as observed according to treatment received at the start of this study (i.e., adalimumab 40 mg eow or adalimumab 80 mg eow) regardless of subsequent dose escalation. Data are summarized according to participants' cumulative exposure to adalimumab in Study M04-688 (NCT00338754) and this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: adalimumab
Biological: adalimumab
Adalimumab 40 mg every other week, subcutaneous
Also known as: ABT-D2E7, Humira
Adalimumab 80 mg every other week, subcutaneous
Also known as: ABT-D2E7, Humira
Number of Participants With a 50% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI50 Response)
PASI scores range from 0 (best outcome) to 72 (worst outcome including erythema, induration, desquamation, and area affected). Baseline is defined as the last available PASI value prior to the first dose of study drug (adalimumab or placebo) in Study M04-688 (NCT00338754).
Time frame: Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab
Number of Participants With a 75% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI75 Response)
PASI scores range from 0 (best outcome) to 72 (worst outcome including erythema, induration, desquamation, and area affected). Baseline is defined as the last available PASI value prior to the first dose of study drug (adalimumab or placebo) in Study M04-688 (NCT00338754).
Time frame: Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab
Number of Participants With a 90% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI90 Response)
PASI scores range from 0 (best outcome) to 72 (worst outcome including erythema, induration, desquamation, and area affected). Baseline is defined as the last available PASI value prior to the first dose of study drug (adalimumab or placebo) in Study M04-688 (NCT00338754).
Time frame: Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab
Japanese participants with chronic plaque psoriasis who completed the blinded, placebo-controlled Study M04-688 (NCT00338754; 24-week duration) enrolled in the extension study, M04-702, an open-label study until adalimumab received approval for treatment of psoriasis in Japan.
| Milestone | Adalimumab 40 mg Every Other Week | Adalimumab 80 mg Every Other Week |
|---|---|---|
| Started | 89 | 58 |
| Completed | 67 | 45 |
| Not completed | 22 | 13 |
PASI scores range from 0 (best outcome) to 72 (worst outcome including erythema, induration, desquamation, and area affected). Baseline is defined as the last available PASI value prior to the first dose of study drug (adalimumab or placebo) in Study M04-688 (NCT00338754).
| Participants | Adalimumab 40 mg Every Other Week | Adalimumab 80 mg Every Other Week |
|---|---|---|
| 12 weeks (N = 89 [40 mg eow] and 57 [80 mg eow]) | 78 | 54 |
| 24 weeks (N = 88 [40 mg eow] and 56 [80 mg eow]) | 80 | 55 |
| 36 weeks (N = 87 [40 mg eow] and 54 [80 mg eow]) | 79 | 52 |
| 52 weeks (N = 85 [40 mg eow] and 52 [80 mg eow]) | 80 | 51 |
| 76 weeks (N = 80 [40 mg eow] and 52 [80 mg eow]) | 76 | 52 |
| 100 weeks (N = 78 [40 mg eow] and 52 [80 mg eow]) | 75 | 49 |
| 160 weeks (N = 71 [40 mg eow] and 47 [80 mg eow]) | 71 | 47 |
| 208 weeks (N = 29 [40 mg eow] and 14 [80 mg eow]) | 29 | 14 |
PASI scores range from 0 (best outcome) to 72 (worst outcome including erythema, induration, desquamation, and area affected). Baseline is defined as the last available PASI value prior to the first dose of study drug (adalimumab or placebo) in Study M04-688 (NCT00338754).
| Participants | Adalimumab 40 mg Every Other Week | Adalimumab 80 mg Every Other Week |
|---|---|---|
| 12 weeks (N = 89 [40 mg eow] and 57 [80 mg eow]) | 54 | 45 |
| 24 weeks (N = 88 [40 mg eow] and 56 [80 mg eow]) | 69 | 50 |
| 36 weeks (N = 87 [40 mg eow] and 54 [80 mg eow]) | 65 | 51 |
| 52 weeks (N = 85 [40 mg eow] and 52 [80 mg eow]) | 67 | 48 |
| 76 weeks (N = 80 [40 mg eow] and 52 [80 mg eow]) | 70 | 47 |
| 100 weeks (N = 78 [40 mg eow] and 52 [80 mg eow]) | 66 | 43 |
| 160 weeks (N = 71 [40 mg eow] and 47 [80 mg eow]) | 69 | 41 |
| 208 weeks (N = 29 [40 mg eow] and 14 [80 mg eow]) | 27 | 13 |
PASI scores range from 0 (best outcome) to 72 (worst outcome including erythema, induration, desquamation, and area affected). Baseline is defined as the last available PASI value prior to the first dose of study drug (adalimumab or placebo) in Study M04-688 (NCT00338754).
| Participants | Adalimumab 40 mg Every Other Week | Adalimumab 80 mg Every Other Week |
|---|---|---|
| 12 weeks (N = 89 [40 mg eow] and 57 [80 mg eow]) | 31 | 29 |
| 24 weeks (N = 88 [40 mg eow] and 56 [80 mg eow]) | 50 | 39 |
| 36 weeks (N = 87 [40 mg eow] and 54 [80 mg eow]) | 54 | 44 |
| 52 weeks (N = 85 [40 mg eow] and 52 [80 mg eow]) | 54 | 42 |
| 76 weeks (N = 80 [40 mg eow] and 52 [80 mg eow]) | 55 | 38 |
| 100 weeks (N = 78 [40 mg eow] and 52 [80 mg eow]) | 55 | 35 |
| 160 weeks (N = 71 [40 mg eow] and 47 [80 mg eow]) | 57 | 33 |
| 208 weeks (N = 29 [40 mg eow] and 14 [80 mg eow]) | 23 | 12 |
Collected over Adverse events are reported starting from the first dose of adalimumab (in Study M04-688 [NCT00338754] or in Study M04-702) up to 70 days after the last dose of adalimumab.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab 40 mg Every Other Week | — | 19/89 (21.3%) | 88/89 (98.9%) |
| Adalimumab 80 mg Every Other Week | — | 11/58 (19%) | 58/58 (100%) |
| Event | Adalimumab 40 mg Every Other Week | Adalimumab 80 mg Every Other Week |
|---|---|---|
| Angina pectorisCardiac disorders | 1/89 | 2/58 |
| Acute myocardial infarctionCardiac disorders | 0/89 | 1/58 |
| Inguinal herniaGastrointestinal disorders | 0/89 | 1/58 |
| Viral infectionInfections and infestations | 0/89 | 1/58 |
| Rib fractureInjury, poisoning and procedural complications | 0/89 | 1/58 |
| Thermal burnInjury, poisoning and procedural complications | 0/89 | 1/58 |
| AdenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/89 | 1/58 |
| Cerebral infarctionNervous system disorders | 1/89 | 1/58 |
| EncephalitisNervous system disorders | 0/89 | 1/58 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/89 | 1/58 |
| Event | Adalimumab 40 mg Every Other Week | Adalimumab 80 mg Every Other Week |
|---|---|---|
| NasopharyngitisInfections and infestations | 67/89 | 45/58 |
| Blood triglycerides increasedInvestigations | 22/89 | 17/58 |
| Blood creatine phosphokinase increasedInvestigations | 21/89 | 15/58 |
| DiarrhoeaGastrointestinal disorders | 20/89 | 14/58 |
| FolliculitisInfections and infestations | 21/89 | 14/58 |
| Alanine aminotransferase increasedInvestigations | 21/89 | 9/58 |
| Antinuclear antibody increasedInvestigations | 21/89 | 8/58 |
| Back painMusculoskeletal and connective tissue disorders | 19/89 | 10/58 |
| HeadacheNervous system disorders | 19/89 | 8/58 |
| Dental cariesInfections and infestations | 18/89 | 6/58 |
| Age, Categorical(Participants) | Adalimumab 40 mg Every Other Week | Adalimumab 80 mg Every Other Week | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 80 | 56 | 136 |
| >=65 years | 9 | 2 | 11 |
| Age Continuous(years) | Adalimumab 40 mg Every Other Week | Adalimumab 80 mg Every Other Week | Total |
|---|---|---|---|
| Mean | 45.1 ± 13.39 | 42.9 ± 11.88 | 44.2 ± 12.82 |
| Sex: Female, Male(Participants) | Adalimumab 40 mg Every Other Week | Adalimumab 80 mg Every Other Week | Total |
|---|---|---|---|
| Female | 13 | 10 | 23 |
| Male | 76 | 48 | 124 |
| Region of Enrollment(participants) | Adalimumab 40 mg Every Other Week | Adalimumab 80 mg Every Other Week | Total |
|---|---|---|---|
| Japan | 89 | 58 | 147 |
The record gives a start of Apr 2006, a primary completion of Sep 2007 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab